{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:44:53Z","timestamp":1788443093901,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.pharma.2025.03.001","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T20:01:02Z","timestamp":1741636862000},"page":"876-889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Regulatory frameworks and filing discrepancies in generic drug approvals: A cross-regional study with analysis of FDA ANDA deficiencies"],"prefix":"10.1016","volume":"83","author":[{"given":"Jyoti","family":"Pawar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2025.03.001_bib0230","unstructured":"Torsten Schnetgoeke M. Sc. Senior Manager RA. Whitepaper differing cmc requirements: US and EU n.d. https:\/\/www.pharmalex.com\/wp-content\/uploads\/2018\/08\/Whitepaper-CMC-Differences-US-vs-EU_-T-Schnetgoeke.pdf (accessed December 13, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0235","unstructured":"Seema Ledan PCPSSSM. Discussing brand versus generic medications 2020. https:\/\/www.uspharmacist.com\/article\/discussing-brand-versus-generic-medications (accessed December 13, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0240","unstructured":"ICH Official web site: ICH n.d. https:\/\/www.ich.org\/ (accessed December 9, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0245","unstructured":"ICH reflection paper further opportunities for harmonization of standards for generic drugs 1 2018. http:\/\/apps.who.int\/medicinedocs\/en\/m\/abstract\/Js23011en\/."},{"key":"10.1016\/j.pharma.2025.03.001_bib0250","unstructured":"Fda, Cder, Sollenberger, Michelle. ANDA submissions\u00a0\u2014\u00a0content and format guidance for industry rev. 1 2019. http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htmand\/orhttp:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm (accessed October 20, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0255","unstructured":"European Medicines Agency. European-medicines-agency-procedural-advice-users-centralised-procedure-generic-hybrid-applications_en n.d. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/european-medicines-agency-pre-authorisation-procedural-advice-users-centralised-procedure_en.pdf (accessed December 13, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0260","unstructured":"BA\/BE n.d. https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/bioequi_bioavail\/ (accessed November 20, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0265","unstructured":"NMPA issues requirements for registration classification and application dossiers of chemical drugs n.d. https:\/\/english.nmpa.gov.cn\/2020-06\/30\/c_528659.htm (accessed October 20, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0270","unstructured":"Vinaykumar KM, Venkatesh MP. Comparison of regulatory requirements for filing of generic drug product in USA and China n.d. www.cfda.gov.cn."},{"key":"10.1016\/j.pharma.2025.03.001_bib0275","unstructured":"Generic drugs program activities report\u00a0\u2013\u00a0FY 2022 monthly performance\u00a0|\u00a0FDA n.d. https:\/\/www.fda.gov\/drugs\/abbreviated-new-drug-application-anda\/generic-drugs-program-activities-report-fy-2022-monthly-performance (accessed October 21, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0280","unstructured":"Activities report of the generic drugs program (FY 2019) monthly performance\u00a0|\u00a0FDA n.d. https:\/\/www.fda.gov\/drugs\/abbreviated-new-drug-application-anda\/activities-report-generic-drugs-program-fy-2019-monthly-performance (accessed November 12, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0285","unstructured":"Activities report of the generic drugs program (FY 2020) monthly performance\u00a0|\u00a0FDA n.d. https:\/\/www.fda.gov\/drugs\/abbreviated-new-drug-application-anda\/activities-report-generic-drugs-program-fy-2020-monthly-performance (accessed November 12, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0290","unstructured":"Activities report of the generic drugs program (FY 2021) monthly performance\u00a0|\u00a0FDA n.d. https:\/\/www.fda.gov\/drugs\/abbreviated-new-drug-application-anda\/activities-report-generic-drugs-program-fy-2021-monthly-performance (accessed November 12, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0295","unstructured":"Generic drugs program activities report\u00a0\u2013\u00a0FY 2023 monthly performance\u00a0|\u00a0FDA n.d. https:\/\/www.fda.gov\/drugs\/abbreviated-new-drug-application-anda\/generic-drugs-program-activities-report-fy-2023-monthly-performance (accessed November 12, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0300","unstructured":"FDA. Good ANDA submission practices guidance for industry 2022. https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/guidances-drugs (accessed October 21, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0305","unstructured":"Fda, Cder. ANDA submissions-amendments to abbreviated new drug applications under GDUFA guidance for industry 2024. https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/guidances-drugs."},{"key":"10.1016\/j.pharma.2025.03.001_bib0310","unstructured":"Fda, Cder, Ogdp. Manual of policies and procedures center for drug evaluation and research MAPP 5220.3 policy and procedures office of generic drugs communicating certain deficiencies identified during filing review of ANDAs n.d. https:\/\/www.fda.gov\/media\/107774\/download (accessed November 23, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0315","unstructured":"ANDA submissions\u00a0\u2013\u00a0refuse-to-receive standards: questions and answers guidance for industry\u00a0|\u00a0FDA n.d. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/anda-submissions-refuse-receive-standards-questions-and-answers-guidance-industry (accessed July 30, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0320","doi-asserted-by":"crossref","first-page":"107295","DOI":"10.1016\/j.vascn.2023.107295","article-title":"Common chemistry, manufacturing, and control deficiencies in abbreviated new drug applications assessed by the US Food and drug administration: hurdle to access cost-effective medicines","volume":"123","author":"Kulkarni","year":"2023","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.pharma.2025.03.001_bib0325","unstructured":"Fda, Cder. Manual of policies and procedures center for drug evaluation and research MAPP 5220.5 Rev. 2 policy and procedures office of generic drugs issuance of information requests and\/or discipline review letters for abbreviated new drug applications 2024. https:\/\/www.fda.gov\/media\/109649\/download (accessed November 23, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0330","unstructured":"Fda, Cder. FDA fact sheet: what's involved in reviewing and approving generic drug applications? (PDF) n.d. https:\/\/fda.report\/media\/99163\/FDA-Fact-Sheet--What%27s-Involved-in-Reviewing-and-Approving-Generic-Drug-Applications--%28PDF%29.pdf (accessed November 23, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0335","unstructured":"Generic and hybrid medicines\u00a0|\u00a0European Medicines Agency (EMA) n.d. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/marketing-authorisation\/generic-hybrid-medicines (accessed December 9, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0340","unstructured":"Ministry of Health L and W (MHLW). 4th India-Japan medical products regulatory symposium regulatory system on Generic drugs in Japan n.d. https:\/\/www.pmda.go.jp\/files\/000234055.pdf (accessed December 13, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0345","unstructured":"NMPA issues requirements for registration classification and application dossiers of chemical drugs n.d. https:\/\/english.nmpa.gov.cn\/2020-06\/30\/c_528659.htm (accessed December 9, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0350","unstructured":"Press Release: Press Information Bureau n.d. https:\/\/pib.gov.in\/PressReleasePage.aspx?PRID=1705065 (accessed December 9, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0355","unstructured":"Drug administration law of the People's Republic of China n.d. https:\/\/english.nmpa.gov.cn\/2019-09\/26\/c_773012.htm (accessed December 9, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0360","unstructured":"Abbreviated new drug application (ANDA) forms and submission requirements\u00a0|\u00a0FDA n.d. https:\/\/www.fda.gov\/drugs\/abbreviated-new-drug-application-anda\/abbreviated-new-drug-application-anda-forms-and-submission-requirements (accessed December 9, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0365","unstructured":"ANDA submissions\u00a0\u2014\u00a0content and format of abbreviated new drug applications\u00a0|\u00a0FDA n.d. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/anda-submissions-content-and-format-abbreviated-new-drug-applications (accessed December 9, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0370","unstructured":"Documents to be submitted for grant of permission to conduct bioequivalence studies for export purpose n.d. https:\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadAlertsFiles\/BEGuideline.pdf (accessed December 13, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0375","unstructured":"How to submit abbreviated new drug application (ANDA) for generic drugs in China\u00a0|\u00a0ChemLinked n.d. https:\/\/baipharm.chemlinked.com\/insights\/generic-drug-application-anda-in-china (accessed October 19, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0380","unstructured":"Central drugs standard control organization. Guidance document for BA\/BE NOC for export purpose as per schedule Y & test licence in form 11 Of Drugs And Cosmetics Rules, 1945 BA\/BE NOC for export division n.d. https:\/\/cdsco.gov.in\/opencms\/export\/sites\/CDSCO_WEB\/Pdf-documents\/BA_BE\/guidance_doc_BABE_NOC1_1Jan2018.pdf (accessed December 13, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0385","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Guideline on the investigation of bioequivalence discussion in the joint efficacy and quality working group adoption rev. 1 1997. http:\/\/www.ema.europa.eu."},{"key":"10.1016\/j.pharma.2025.03.001_bib0390","unstructured":"ANDAs: stability testing of drug substances and products, questions and answers\u00a0|\u00a0FDA n.d. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/andas-stability-testing-drug-substances-and-products-questions-and-answers (accessed December 10, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0395","unstructured":"Food and Drug Administration. Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA guidance for industry draft guidance n.d. http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm."},{"key":"10.1016\/j.pharma.2025.03.001_bib0400","unstructured":"Food and Drug Administration. Guidance for Industry bioavailability and bioequivalence studies for orally administered drug products-general considerations 2003. http:\/\/www.fda.gov\/cder\/guidance\/index.htm."},{"key":"10.1016\/j.pharma.2025.03.001_bib0405","unstructured":"eCFR:: 21 CFR part 320\u00a0\u2013\u00a0bioavailability and bioequivalence requirements n.d. https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-D\/part-320 (accessed December 10, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0410","unstructured":"Pharmaceutical and Medical Device Agency. Guideline for bioequivalence studies of generic products 2020. https:\/\/www.nihs.go.jp\/drug\/be-guide(e)\/2020\/GL1_BE_2020.pdf (accessed December 14, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0415","unstructured":"Notice on soliciting public opinions on the \u201cSummary of bioequivalence studies of generic chemical drugs (draft for comments)\u201d n.d. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/c30bb8434773a93c5164ca1d8231fa26 (accessed December 10, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0420","unstructured":"Medicines Agency E. Q & A on implementation of Ph.Eur. Medicinal Product Monographs 2023. www.ema.europa.eu\/contact."},{"key":"10.1016\/j.pharma.2025.03.001_bib0425","unstructured":"CVM GFI #285\u00a0\u2013\u00a0manufacture of batches in support of original NADAs, ANADAs, and CNADAs\u00a0|\u00a0FDA n.d. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/cvm-gfi-285-manufacture-batches-support-original-nadas-anadas-and-cnadas (accessed December 10, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0430","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.drudis.2018.06.018","article-title":"Marketing authorisation applications submitted to the European Medicines Agency by small and medium-sized enterprises: an analysis of major objections and their impact on outcomes","volume":"23","author":"Amaouche","year":"2018","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.pharma.2025.03.001_bib0435","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1208\/s12249-017-0892-0","article-title":"Quality issues identified during the evaluation of biosimilars by the European Medicines Agency's Committee for medicinal products for human use","volume":"19","author":"Cilia","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.pharma.2025.03.001_bib0440","unstructured":"View of where is industry getting it wrong? A review of quality concerns raised at day 120 by the Committee for medicinal products for human use during European centralised marketing authorisation submissions for chemical entity medicinal products n.d. https:\/\/journals.library.ualberta.ca\/jpps\/index.php\/JPPS\/article\/view\/6525\/5440 (accessed December 10, 2024)."},{"key":"10.1016\/j.pharma.2025.03.001_bib0445","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/1741134312448062","article-title":"Deficiencies in generic product dossiers as submitted to the WHO Prequalification of Medicines Programme","volume":"9","author":"Worku","year":"2012","journal-title":"J. Generic Med."},{"key":"10.1016\/j.pharma.2025.03.001_bib0450","unstructured":"Common deficiencies in finished pharmaceutical product (FPP) dossiers\u00a0\u2013\u00a0additional guidance to manufacturers\u00a0|\u00a0WHO\u00a0\u2013\u00a0prequalification of medical products (IVDs, medicines, vaccines and immunization devices, vector control) n.d. https:\/\/extranet.who.int\/prequal\/news\/common-deficiencies-finished-pharmaceutical-product-fpp-dossiers-additional-guidance (accessed December 10, 2024)."}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450925000434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450925000434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T08:45:00Z","timestamp":1755765900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450925000434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0003450925000434"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2025.03.001","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regulatory frameworks and filing discrepancies in generic drug approvals: A cross-regional study with analysis of FDA ANDA deficiencies","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2025.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}